| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Oncology, Markers, Clinical Correlates |
1 Division of Biological Sciences, and 2 Department of Surgery, University of Missouri, Columbia, Missouri; and 3 Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
Purpose: Proteomic analysis of breast nipple aspirate fluid (NAF) holds promise as a noninvasive method to identify markers of breast cancer. The objectives of the study were to: (a) describe the NAF proteome, (b) identify candidate markers of breast cancer in NAF by using proteomic analysis, and (c) validate the markers identified by using a quantitative, high-throughput ELISA analysis.
Experimental Design: For proteome analysis, NAF proteins from a single subject without breast cancer were separated by two-dimensional PAGE and were subjected to matrix-assisted laser desorption ionization time-of-flight mass spectometry identification. A total of 41 different proteins were identified, 25 of which were known to be secreted. To identify breast cancer markers, we separated 20 NAF samples (10 normal, 10 cancer) by two-dimensional PAGE. Three protein spots were detected that were up-regulated in three or more cancer samples. These spots were identified to be gross cystic disease fluid protein (GCDFP)-15, apolipoprotein D (apoD), and 
1-acid glycoprotein (AAG). To validate these three potential biomarkers, 105 samples (53 from benign breasts and 52 from breasts with cancer) were analyzed using ELISA.
Results: Among all of the subjects, GCDFP-15 levels were lower (P < 0.001) and AAG levels were higher (P = 0.001) in breasts with cancer. This was also true in premenopausal (GCDFP-15, P = 0.011; AAG, P = 0.002) but not in postmenopausal women. GCDFP-15 levels were lowest (P = 0.003) and AAG levels highest (P < 0.001) in women with ductal carcinoma in situ (DCIS). Menopausal status influenced GCDFP-15 and AAG more in women without breast cancer than in women with breast cancer. apoD levels did not correlate significantly with breast cancer.
Conclusions: Our study revealed that the NAF proteome, as defined by two-dimensional PAGE, consists of a limited number of proteins, and that the expression of AAG and GCDFP-15 correlates with disease presence and stage.
This article has been cited by other articles:
|
|
 |
|
  A. LEBRECHT, D. BOEHM, M. SCHMIDT, H. KOELBL, and F. H. GRUS Surface-enhanced Laser Desorption/Ionisation Time-of-flight Mass Spectrometry to Detect Breast Cancer Markers in Tears and Serum Cancer Genomics Proteomics, March 1, 2009; 6(2): 75 - 83. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S.-J. Li, M. Peng, H. Li, B.-S. Liu, C. Wang, J.-R. Wu, Y.-X. Li, and R. Zeng Sys-BodyFluid: a systematical database for human body fluid proteome research Nucleic Acids Res., January 1, 2009; 37(suppl_1): D907 - D912. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Huang, K. E. Anderson, M. Nagamani, J. J. Grady, and L.-J. W. Lu Dietary Intake of Lactose as a Strong Predictor for Secretor Status of Nipple Aspirate Fluid in Healthy Premenopausal Nonlactating Women Clin. Cancer Res., March 1, 2008; 14(5): 1386 - 1392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. R. Somerfield, D. F. Hayes, and R. C. Bast Jr American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer J. Clin. Oncol., November 20, 2007; 25(33): 5287 - 5312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Kulasingam and E. P. Diamandis Proteomics Analysis of Conditioned Media from Three Breast Cancer Cell Lines: A Mine for Biomarkers and Therapeutic Targets Mol. Cell. Proteomics, November 1, 2007; 6(11): 1997 - 2011. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. L. McCaw, A. S. Chan, A. L. Stegner, B. Mooney, J. N. Bryan, S. E. Turnquist, C. J. Henry, H. Alexander, and S. Alexander Proteomics of Canine Lymphoma Identifies Potential Cancer-Specific Protein Markers Clin. Cancer Res., April 15, 2007; 13(8): 2496 - 2503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. Herr, A. V. Hatch, D. J. Throckmorton, H. M. Tran, J. S. Brennan, W. V. Giannobile, and A. K. Singh Microfluidic immunoassays as rapid saliva-based clinical diagnostics PNAS, March 27, 2007; 104(13): 5268 - 5273. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Mannello and G. A.M. Tonti Benign Breast Diseases: Classification, Diagnosis, and Management Oncologist, November 1, 2006; 11(10): 1132 - 1134. [Full Text] [PDF]
|
|
|
|
|
|
F. Bertucci, D. Birnbaum, and A. Goncalves Proteomics of Breast Cancer: Principles and Potential Clinical Applications Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. S. Azad, N. Rasool, C. M. Annunziata, L. Minasian, G. Whiteley, and E. C. Kohn Proteomics in Clinical Trials and Practice: Present Uses and Future Promise Mol. Cell. Proteomics, October 1, 2006; 5(10): 1819 - 1829. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. S. Dua, C. M. Isacke, and G. P.H. Gui The Intraductal Approach to Breast Cancer Biomarker Discovery J. Clin. Oncol., March 1, 2006; 24(7): 1209 - 1216. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J Fabian, B F Kimler, M S Mayo, and S A Khan Breast-tissue sampling for risk assessment and prevention Endocr. Relat. Cancer, June 1, 2005; 12(2): 185 - 213. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
